Persistency with latanoprost or timolol in primary open-angle glaucoma suspects

American Journal of Ophthalmology

Volumn 137, Issue SUPPL., 2004, Pages

  Schwartz, Gail F ^a,b,e   Reardon, Gregory ^c   Mozaffari, Essy ^d  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c Informagenics LLC   (United States)

^d PFIZER INC   (United States)

^e NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETAXOLOL; BIMATOPROST; BRIMONIDINE; DORZOLAMIDE; LATANOPROST; TIMOLOL; TRAVOPROST;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; DRUG USE; DRUG WITHDRAWAL; FEMALE; GLAUCOMA; HEALTH MAINTENANCE ORGANIZATION; HUMAN; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MEDICARE; MONOTHERAPY; OPEN ANGLE GLAUCOMA; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; REGRESSION ANALYSIS; RETROSPECTIVE STUDY;

EID: 0346493017     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2003.10.034     Document Type: Article

References (16)

1. Preferred practice patterns of primary open-angle glaucoma suspect. 2002;American Academy of Ophthalmology, San Francisco.
2. Kass M.A., Heuer D.K., Higginbotham E.J., et al. The Ocular Hypertension Treatment Study a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma . Arch Ophthalmol. 120:2002;701-713.
3. Schwartz G.F. Measuring persistency with drug therapy in glaucoma management. Am J Manag Care. 8:(Suppl):2002;S237-S239.
4. Daily Health Policy Report. Prescription drugs - study looks at effect of cost on California seniors' prescription drug practices (Nov 1, 2002). Available at: http://www.kaisernetwork.org/daily_reports/rep_index.cfm?hint= 3&DR_ ID=14385. Accessed on October 7, 2003.
5. Johnson E.S., Mozaffari E. Measuring patient persistency with drug therapy using methods for the design and analysis of natural history studies. Am J Manag Care. 8:(Suppl):2002;S249-S254.
6. Bland J.M., Altman D.G. Survival probabilities (the Kaplan-Meier method). BMJ. 317:1998;1572.
7. Dasgupta S., Oates V., Bookhart B.K., Vaziri B., Schwartz G.F., Mozaffari E. Population-based persistency rates for topical glaucoma medications measured with pharmacy claims data. Am J Manag Care. 8:(Suppl):2002;S255-S261.
8. Reardon G, Schwartz GF, Mozaffari E. Patient persistency with topical ocular hypotensive therapy in a managed care population. Am J Ophthalmol 2004;137(Suppl):S3-S12.
9. Shaya F.T., Mullins C.D., Wong W., Cho J. Discontinuation rates of topical glaucoma medications in a managed care population. Am J Manag Care. 8:(Suppl):2002;S271-S277.
10. Spooner J.J., Bullano M.F., Ikeda L.I., et al. Rates of discontinuation and change of glaucoma therapy in a managed care setting. Am J Manag Care. 8:(Suppl):2002;S262-S270.
11. Reardon G., Schwartz G.F., Mozaffari E. Patient persistency with topical prostaglandin therapy in the management of glaucoma. Clin Ther. 25:2003;1172-1185.
12. Alm A., Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Ophthalmology. 102:1995;1743-1752.
13. Camras C.B. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma. A six-month, masked, multicenter trial in the United States. Ophthalmology. 103:1996;138-147.
14. Mishima H.K., Masuda K., Kitazawa Y., Azuma I., Araie M. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study. Arch Ophthalmol. 114:1996;929-932.
15. Watson P., Stjernschantz J. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology. 103:1996;126-137.
16. Patel S.C., Spaeth G.L. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg. 26:1995;233-236.